Transforming Cancer Care:
From Treating a Diagnosis to Treating the Patient
BostonGene provides comprehensive molecular and immune profiling to assist in treatment selection
Why BostonGene
Partners
-
Strategic alliance with MD Anderson to advance personalized cancer diagnostics and treatments. -
BostonGene announces new master agreement with New York’s Memorial Sloan Kettering Cancer Center -
Mayo Clinic and BostonGene collaborate to uncover key tumor characteristics that can be exploited to develop personalized therapies for lymphoma patients
BostonGene Approach
Our AI-based molecular and immune profiling identifies the most effective treatment options for every cancer patient
Diagnose
Comprehensive testing for each cancer patient
Predict and Monitor
Cancer therapy response
Innovate
The landscape of precision medicine
Simplify
User-friendly treatment guidelines for care teams
Discover
New tools for oncologists
Evolve
Cancer profiling databases
News
BostonGene Announces Integration with NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status
BostonGene and WellDyne Announce Strategic Partnership to Predict Immunotherapy Response and Reduce Overall Cost of Care in Cancer
- BostonGene Announces Integration with NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
- BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status
- BostonGene and WellDyne Announce Strategic Partnership to Predict Immunotherapy Response and Reduce Overall Cost of Care in Cancer
Questions
Contact us